Last reviewed · How we verify

NCT04666883

Splenic Hilar Nodes in Splenic Flexure Cancer

Status unknown Last updated 29 December 2020
What this trial tests

trial testing Review of records and follow up in Colon Cancer in 20 participants. Status unknown.

Timeline
1 January 2021
Primary endpoint
1 March 2021
1 March 2021

Quick facts

Lead sponsorUniversity of Rome Tor Vergata
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment20
Start date1 January 2021
Primary completion1 March 2021
Estimated completion1 March 2021
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

University of Rome Tor Vergata

Who can join

Eligibility, any sex, with Colon Cancer or Metastases, Lymphatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Report the incidence of metastases to the splenic hilar lymphnodes from splenic flexure primaries. This mode of spread has not been previously characterized for these tumours.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Colon Cancer

Currently open trials in the same condition.

Other University of Rome Tor Vergata trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04666883.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing